PMID- 23580032
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20211021
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 270
IP  - 8
DP  - 2013 Aug
TI  - Silibinin induced the apoptosis of Hep-2 cells via oxidative stress and 
      down-regulating survivin expression.
PG  - 2289-97
LID - 10.1007/s00405-013-2444-x [doi]
AB  - Silibinin is an anticancer and chemopreventive natural compound, which is 
      extracted from milk thistle (Silybum marianum). It is reported that silibinin has 
      anticancer efficacy in many malignant tumors. Laryngeal carcinoma is the second 
      most common head and neck squamous carcinoma. In the present work, we 
      investigated the effects of silibinin on laryngeal squamous cell carcinoma (LSCC) 
      cell line Hep-2 cells. We found that silibinin induced the decrease of cell 
      viability in Hep-2 cells with a concentration- and time-dependent manner. 
      Moreover, silibinin resulted in the apoptosis of Hep-2 cells and had synergy 
      effects with arsenic trioxide. Intracellular reactive oxygen species (ROS) 
      accumulation increased because of silibinin exposure. ROS scavenger NAC 
      alleviated the cytotoxicity of silibinin to Hep-2 cells. The mitochondrial 
      membrane potential (MMP) was lost in Hep-2 cells treated with silibinin. 
      Subsequently, silibinin induced the activation of caspase-3 in Hep-2 cells and 
      caspase inhibitor Z-VAD-FMK inhibited the cytotoxicity of silibinin in Hep-2 
      cells. The survivin expression decreased after Hep-2 cells were treated with 
      silibinin. In conclusion, silibinin induced the apoptosis of Hep-2 cells via 
      oxidative stress and down-regulating survivin expression. Therefore, silibinin is 
      a potential therapeutical agent against LSCC in future.
FAU - Yang, Xinxin
AU  - Yang X
AD  - Jining Medical University, Jining, Shandong Province, People's Republic China. 
      yangxinxin1979@yahoo.com.cn
FAU - Li, Xiaoyu
AU  - Li X
FAU - An, Liangxiang
AU  - An L
FAU - Bai, Bo
AU  - Bai B
FAU - Chen, Jing
AU  - Chen J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130412
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Antioxidants)
RN  - 0 (Arsenicals)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oxides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Silymarin)
RN  - 0 (Survivin)
RN  - 4RKY41TBTF (Silybin)
RN  - EC 3.4.22.- (Caspase 3)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/*pharmacology
MH  - Antioxidants/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Arsenic Trioxide
MH  - Arsenicals/pharmacology
MH  - Carcinoma, Squamous Cell/metabolism/pathology
MH  - Caspase 3/analysis
MH  - Cell Line, Tumor
MH  - Down-Regulation
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/*drug effects/genetics/metabolism
MH  - Laryngeal Neoplasms/metabolism/pathology
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - Neoplasm Proteins/metabolism
MH  - Oxidative Stress/drug effects
MH  - Oxides/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Reactive Oxygen Species
MH  - Silybin
MH  - Silymarin/*pharmacology
MH  - Survivin
EDAT- 2013/04/13 06:00
MHDA- 2014/08/19 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/12/14 00:00 [received]
PHST- 2013/03/08 00:00 [accepted]
PHST- 2013/04/13 06:00 [entrez]
PHST- 2013/04/13 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
AID - 10.1007/s00405-013-2444-x [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2013 Aug;270(8):2289-97. doi: 
      10.1007/s00405-013-2444-x. Epub 2013 Apr 12.